Heights Initiates MRI Study on Menopause Brain Health, Utilising N-of-1 Nutrition Design
UK brand Heights, in partnership with the University of East Anglia, has launched an MRI neuroimaging study investigating specific nutrient impacts on menopausal brain health. This N-of-1 design offers deep mechanistic insights, presenting a potential new model for substantiating supplement claims beyond traditional RCTs.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
London, United Kingdom — 22 July 2026
UK supplement brand Heights, in collaboration with the University of East Anglia, has commenced an MRI neuroimaging study to assess the impact of targeted nutrition on brain health during menopause. The study, focusing on Heights' Vitals multivitamin (containing bioavailable B vitamins and omega-3 fatty acids), aims to determine how supplementation influences brain function, cerebral blood flow, and structure, while accounting for hormonal fluctuations.
Dr. Harry Jarrett, Heights' Director of Science and Research, indicated the research's primary goal is to address short-term symptoms like brain fog and explore long-term brain health benefits, particularly given women's elevated risk for Alzheimer's disease and dementia. The working hypothesis suggests declining oestrogen levels during menopause may compromise brain function, a protective effect that nutrition could mitigate.
The study employs a longitudinal N-of-1 design, wherein a single menopausal participant undergoes 32 MRI scans both pre and post daily multinutrient intervention. This is complemented by cognitive testing and biomarker analysis. Dr. Jarrett stated this methodology provides unprecedented mechanistic detail on how the brain responds to nutritional interventions, contrasting with traditional large-cohort studies often reliant on questionnaires. He advocates for broader industry adoption of such intensive neuroimaging to generate robust scientific evidence.
Dr. Jarrett will present initial findings from this neuroimaging study at the Nutra Healthspan Summit 2026, alongside results from an open-label trial on Heights' Thrive supplement (featuring NAD+ precursors, CoQ10, and trans-resveratrol) and a project on gut microbiome's role in dementia risk, which indicated probiotic interventions improved cognitive function.
What this means for United Kingdom
UK supplement manufacturers must consider investing in more rigorous scientific validation, such as neuroimaging, to support claims for cognitive and women's health products. The N-of-1 study model, while not establishing efficacy like an RCT, provides mechanistic data valuable for product differentiation and consumer trust. Brand owners can leverage such evidence to justify premium pricing and gain market share in the rapidly expanding menopause support category, estimated to be worth £1 billion annually by 2025. Regulatory scrutiny from the MHRA regarding brain health claims will likely increase, necessitating strong scientific backing beyond basic observational data. Companies failing to adapt may see their competitive positioning eroded by brands with superior clinical evidence, impacting sales volumes and market access.
Many leading brands in this category are manufactured in partnership with Supplement Factory.